Strategies to decrease costs of prescribing selective serotonin reuptake inhibitors at a VA Medical Center.
OBJECTIVE
The authors examined the efficacy of a multifaceted intervention designed to contain the cost of prescribing selective serotonin reuptake inhibitors (SSRIs) to inpatients and outpatients served by a Veterans Affairs (VA) medical center.


METHODS
Elements of the intervention included identification of a preferred agent, tablet splitting, education and feedback for prescribers, and an electronic record and ordering system to facilitate changes in prescriber behaviors. VA databases were searched for information on use and costs of antidepressants.


RESULTS
Over 35 months the number of patients treated with SSRIs and the amount spent on SSRIs increased. However, the mean monthly cost per patient decreased from $57.12 to $42.19. The projected cost savings over the 35 months was approximately $700,000; one-fourth of the savings was due to tablet splitting and three-fourths to changes in the proportions of the various SSRIs prescribed. A survey of the top 75 antidepressant prescribers showed that after the educational interventions, 91 percent were aware that citalopram was the medical center's preferred antidepressant, and 59 percent identified it as their own preferred first-line treatment.


CONCLUSIONS
The results suggest that multifaceted interventions can influence antidepressant costs through provider education and changes in pharmacy and computerized information processes, resulting in substantial cost savings for institutions.
Dobscha
Steven K
SK
Portland Veterans Affairs Medical Center, Oregon 97207, USA. dobschas@ohsu.edu
Anderson
Thomas A
TA
Hoffman
William F
WF
Winterbottom
Lisa M
LM
Turner
Erick H
EH
Snodgrass
Leann S
LS
Hauser
Peter
P
D015283:Citalopram / Q000191:economics / Q000627:therapeutic use; D016303:Clinical Pharmacy Information Systems; D003363:Cost Control / Q000379:methods; D017046:Cost Savings; D004334:Drug Administration Schedule; D016527:Drug Costs; D004363:Drug Utilization / Q000191:economics*; D005473:Fluoxetine / Q000191:economics / Q000627:therapeutic use; D016666:Fluvoxamine / Q000191:economics / Q000627:therapeutic use; D017721:Hospital Costs; D006787:Hospitals, Veterans / Q000191:economics*; D006801:Humans; D001523:Mental Disorders / Q000188:drug therapy* / Q000191:economics*; D017374:Paroxetine / Q000191:economics / Q000627:therapeutic use; D017367:Selective Serotonin Reuptake Inhibitors / Q000191:economics* / Q000627:therapeutic use*; D020280:Sertraline / Q000191:economics / Q000627:therapeutic use; D014481:United States
D015283:Citalopram; D005473:Fluoxetine; D016666:Fluvoxamine; D017374:Paroxetine; D017367:Selective Serotonin Reuptake Inhibitors; D020280:Sertraline